Manipal Health Enterprises Ltd, operating on the mainboard and listed on both BSE and NSE, has officially opened its initial public offering (IPO) for public subscription. Investors can bid within the fixed price band of ₹560–₹590 per share. The subscription window is open from 29 July 2026 through 31 July 2026. There is no anchor investor allotment reported for this issue.
Manipal Health Enterprises Ltd is among India’s largest integrated healthcare providers, operating a nationwide network of multi‑specialty hospitals, clinics, and diagnostic centres. The company employs a hub‑and‑spoke model, where flagship tertiary care hospitals are supported by smaller facilities to streamline patient referrals and enhance operational efficiency. It delivers a diversified range of services, including inpatient care, surgeries, diagnostics, pharmacy services, and outpatient consultations.
The network specializes in high‑acuity medical areas such as oncology, cardiology, neurosciences, organ transplants, orthopaedics, and critical care.
This IPO represents a significant opportunity for investors to participate in the healthcare sector, which continues to see robust demand and strategic expansion. In recent months, Manipal Health has executed key acquisitions—including the purchase of hospital property in Mumbai’s Andheri for ₹495 crore and the acquisition of Sahyadri Hospitals in Pune—expanding its bed capacity substantially.
In fiscal 2025, the company reported pro forma revenue of approximately ₹9,263.6 crore, positioning it among the highest‑grossing private hospital chains in India. It has also received SEBI approval for the IPO, which includes a fresh issue component expected to raise a significant amount.
| Attribute | Details |
|---|---|
| IPO Type | Mainboard |
| Listing Platforms | BSE, NSE |
| Price Band | ₹560–₹590 per share |
| Subscription Window | 29–31 July 2026 |
| Anchor Allotment | None reported |
| Use of Proceeds | Debt reduction, acquisitions, expansion (as reported by the company) |
Retail investors seeking exposure to India’s healthcare infrastructure growth may view this IPO as a compelling proposition. As always, potential applicants should consider their investment objectives and risk tolerance before applying.